LANXESS Past Earnings Performance
Past criteria checks 0/6
LANXESS's earnings have been declining at an average annual rate of -66.4%, while the Chemicals industry saw earnings growing at 3.4% annually. Revenues have been growing at an average rate of 2.1% per year.
Key information
-66.4%
Earnings growth rate
-66.3%
EPS growth rate
| Chemicals Industry Growth | 4.3% |
| Revenue growth rate | 2.1% |
| Return on equity | -15.7% |
| Net Margin | -10.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How LANXESS makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6,319 | -690 | 1,167 | 105 |
| 30 Jun 24 | 6,322 | -822 | 1,164 | 102 |
| 31 Mar 24 | 6,422 | -951 | 1,182 | 100 |
| 31 Dec 23 | 6,714 | -843 | 1,238 | 99 |
| 30 Sep 23 | 7,251 | -280 | 1,350 | 102 |
| 30 Jun 23 | 7,835 | -65 | 1,438 | 104 |
| 31 Mar 23 | 8,056 | 128 | 1,439 | 105 |
| 31 Dec 22 | 8,088 | 184 | 1,398 | 102 |
| 30 Sep 22 | 7,794 | 191 | 1,330 | 100 |
| 30 Jun 22 | 7,190 | 147 | 1,229 | 99 |
| 31 Mar 22 | 6,660 | 146 | 1,171 | 96 |
| 31 Dec 21 | 6,101 | 116 | 1,107 | 95 |
| 30 Sep 21 | 5,925 | 119 | 1,050 | 99 |
| 30 Jun 21 | 5,805 | 105 | 1,018 | 100 |
| 31 Mar 21 | 5,772 | 863 | 1,022 | 105 |
| 31 Dec 20 | 6,104 | 892 | 1,056 | 108 |
| 30 Sep 20 | 6,237 | 883 | 1,088 | 110 |
| 30 Jun 20 | 6,480 | 938 | 1,110 | 113 |
| 31 Mar 20 | 6,768 | 231 | 1,127 | 113 |
| 31 Dec 19 | 6,802 | 255 | 1,115 | 114 |
| 30 Sep 19 | 6,559 | 266 | 1,055 | 105 |
| 30 Jun 19 | 6,641 | 243 | 1,066 | 106 |
| 31 Mar 19 | 6,746 | 212 | 1,072 | 106 |
| 31 Dec 18 | 6,824 | 190 | 1,084 | 109 |
| 30 Sep 18 | 7,066 | 144 | 1,166 | 110 |
| 30 Jun 18 | 6,990 | 138 | 1,167 | 109 |
| 31 Mar 18 | 6,873 | 63 | 1,165 | 110 |
| 31 Dec 17 | 6,530 | 23 | 1,111 | 103 |
| 30 Sep 17 | 6,810 | 73 | 1,103 | 116 |
| 30 Jun 17 | 7,021 | 83 | 1,087 | 121 |
| 31 Mar 17 | 7,252 | 166 | 1,072 | 124 |
| 31 Dec 16 | 7,699 | 192 | 1,116 | 131 |
| 30 Sep 16 | 7,590 | 205 | 1,092 | 128 |
| 30 Jun 16 | 7,622 | 184 | 1,093 | 126 |
| 31 Mar 16 | 7,784 | 196 | 1,097 | 128 |
| 31 Dec 15 | 7,902 | 165 | 1,078 | 130 |
| 30 Sep 15 | 8,000 | 82 | 1,060 | 134 |
| 30 Jun 15 | 8,087 | 76 | 1,048 | 141 |
| 31 Mar 15 | 8,001 | 44 | 1,039 | 147 |
| 31 Dec 14 | 8,006 | 47 | 1,052 | 160 |
| 30 Sep 14 | 8,116 | -89 | 1,045 | 176 |
| 30 Jun 14 | 8,126 | -113 | 1,059 | 180 |
| 31 Mar 14 | 8,248 | -159 | 1,075 | 183 |
| 31 Dec 13 | 8,300 | -159 | 1,083 | 186 |
Quality Earnings: 0H7I is currently unprofitable.
Growing Profit Margin: 0H7I is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0H7I is unprofitable, and losses have increased over the past 5 years at a rate of 66.4% per year.
Accelerating Growth: Unable to compare 0H7I's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0H7I is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-13%).
Return on Equity
High ROE: 0H7I has a negative Return on Equity (-15.71%), as it is currently unprofitable.